Skip to main content
AGENUS INC logo

AGENUS INC — Investor Relations & Filings

Ticker · AGEN ISIN · US00847G8042 LEI · 529900NDQQGU5H4UJK81 US Manufacturing
Open in API
Filings indexed 1,574 across all filing types
Latest filing 2026-05-15 Board/Management Inform…
Country US United States of America
Listing US AGEN

About AGENUS INC

https://agenusbio.com/

Agenus Inc. is a clinical-stage biotechnology company specializing in immuno-oncology (I-O). The company discovers, develops, and manufactures therapies designed to activate the body's immune system to combat cancer and infectious diseases. Its portfolio includes a broad range of immunological agents such as antibody therapeutics, adoptive cell therapies, and vaccine adjuvants. A key program is botensilimab, a next-generation CTLA-4 antibody engineered for enhanced efficacy and improved tolerability. Agenus aims to expand the patient population benefiting from I-O, including those with tumors unresponsive to current treatments, by leveraging innovative combination approaches and strategic partnerships.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 91% confidence The document is a Form 8-K ‘Current Report’ filed under Section 13 or 15(d) covering Item 5.02 ‘Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers’. It specifically announces the resignation of the Principal Accounting Officer. This is a management change announcement rather than a full financial report or other event. Therefore it falls under Board/Management Information (MANG).
2026-05-15 English
10-Q - AGENUS INC (0001098972) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - AGENUS INC (0001098972) (Filer)
Regulatory Filings Classification · 92% confidence The document is a SEC Form 8-K current report (Date of Report: May 11, 2026) furnishing an earnings press release as Exhibit 99.1. It is not a standalone earnings release document itself, nor an annual or quarterly report. Under our taxonomy, a Form 8-K is a regulatory filing and does not fit into more specific financial report categories, so it falls into the catch-all “Regulatory Filings” category (RNS).
2026-05-11 English
DEF 14A - AGENUS INC (0001098972) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
SCHEDULE 13G/A - AGENUS INC (0001098972) (Subject)
Major Shareholding Notification
2026-03-26 English
8-K - AGENUS INC (0001098972) (Filer)
Legal Proceedings Report Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a court ruling on a securities class action lawsuit, which is a legal proceeding update. The document does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. It is not a proxy, earnings release, or management discussion. The primary content is about a legal proceeding outcome, making it a Legal Proceedings Report. The document length is 3123 characters, which is typical for an 8-K legal update. Therefore, the appropriate classification is Legal Proceedings Report (LTR).
2026-03-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.